Monoclonal antibody binding to brain membranes is altered by iodonitrotetrazolium violet treatment.
Treatment of brain membrane preparations with para-iodonitrotetrazolium violet, used in preparing synaptic plasma membranes and related fractions, can either increase or decrease monoclonal antibody binding to the membranes. Thus, statements about the absolute amount of antigen present in such fractions cannot be made solely on the basis of antibody binding studies. However, such preparations remain useful as targets for monoclonal antibody screens, and in assays to determine the relative distribution of an antigen. For example, the G5 rat nervous system specific antigen can tentatively be considered a minor, developmentally regulated component of the extra-junctional portion of synaptic plasma membranes.
D000818:Animals; D000911:Antibodies, Monoclonal / Q000032:analysis*; D000941:Antigens / Q000276:immunology; D001666:Binding Sites, Antibody / Q000187:drug effects*; D001921:Brain / Q000187:drug effects / Q000276:immunology*; D051381:Rats; D013570:Synaptic Membranes / Q000187:drug effects / Q000276:immunology*; D013778:Tetrazolium Salts / Q000494:pharmacology*
D000911:Antibodies, Monoclonal; D000941:Antigens; D013778:Tetrazolium Salts; C013574:iodonitrotetrazolium